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BCL-2 Expression is Prognostic for Improved Survival in
Non-small Cell Lung Cancer
Daniel J. Renouf, MD, Richard Wood-Baker, MD, Diana N. Ionescu, MD, Samuel Leung, MSc,
Hamid Masoudi, MD, Cyril B. Gilks, MD, and Janessa Laskin, MD
Objective: We used a large patient population to identify immuno-
histochemical biomarkers to enable improved prognostication in
patients with non-small cell lung carcinoma (NSCLC).
Methods: A tissue microarray was constructed using duplicate 0.6
mm cores of formalin-fixed paraffin-embedded tissue blocks from
609 patients with NSCLC. Immunohistochemical was used to detect
11 biomarkers including epidermal growth factor receptor, Her2,
Her3, p53, p63, bcl-1, bcl-2, Thyroid transcription factor, carcino-
embryonic antigen, chromogranin, and synaptophysin. A clinical
database was generated prospectively at the time of tissue collection.
Survival outcomes were obtained from a Provincial Cancer Registry
database. Univariate and multivariate analyses were performed to
look for a relationship between biomarker expression, smoking
history, and survival.
Results: Survival data for 535 cases were available. As of June
2005, 429 patients (80%) had died; of these 286 (54%) died of lung
cancer, 117 (22%) died of other known causes, and for 26 (5%) the
cause of death was not available. Univariate analysis revealed that
bcl-2 (p  0.007) was the only biomarker prognostic for improved
overall survival (OS). bcl-2 (p  0.021) and p63 (p  0.025) were
both found to be prognostic for improved disease-specific survival
(DSS). Multivariate analysis (using age and biomarker expression)
revealed that bcl-2 expression is prognostic for improved OS (p 
0.005) and DSS (p  0.021).
Conclusions: Our results suggest that bcl-2 expression is prognostic
for improved OS and DSS in NSCLC. Testing for bcl-2 expression
in a prospective study will help to determine its clinical relevance in
prognostication.
Key Words: Non-small cell lung cancer, Prognostic markers, Im-
munohistochemistry, bcl-2, EGFR.
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Lung cancer is the most prevalent of all cancers in NorthAmerica. Non-small cell lung cancer (NSCLC) comprises
the majority of lung cancer and there are a number of factors
known to affect prognosis. The most useful prognostic factor
is stage of the disease.1 Other prognostic factors include
surgically resectability of the tumor2 and pathologic features
such as tumor size,3 histologic subtype,4 lymphatic and blood
vessel invasion,5 and tumor differentiation.6 Useful clinical
prognostic factors include performance statutes and weight
loss.7 Recently, there has been a great deal of interest in using
molecular markers to refine prognosis.
Immunohistochemical (IHC) markers in NSCLC have
been the subject of a recent review8 that divided them into
several groups based on the proposed function of the mole-
cule. One such group is molecules responsible for the self-
sufficiency of growth pathway, and includes epidermal
growth factor receptor (EGFR), Her 2, and cyclin D1. Studies
of the prognostic value of EGFR expression reported variable
results, some suggesting a negative association,9,10 and other
studies failing to find any prognostic significance.11,12 Studies
of Her 2 have also revealed conflicting results.13–15 Cyclin
D1, which causes rearrangement of bcl-1,16 has been found to
be associated with a negative prognosis.17
A second group of markers studied are those involved
in resistance to apoptosis, particularly p53 and bcl-2. Studies
of p53 have found conflicting results regarding progno-
sis,18–20 whereas its analogue p63 has been suggested to have
a positive prognostic value.21 The prognostic utility of bcl-2
was recently reviewed in a meta-analysis that concluded that
bcl-2 expression is associated with a positive prognosis.22
Other markers that have been examined include chro-
mogranin (Ch) and synaptophysin (SNP), both neuroendo-
crine markers with unclear prognostic significance. Thyroid
transcription factor (TTF-1), a lung cancer tumor marker,23
and carcinoembryonic antigen (CEA)24 are also potentially
useful markers with uncertain prognostic significance.
In a review of IHC markers of prognosis in NSCLC,
Zhu et al. described the inconsistent results found with most
markers.8 These findings may be explained by the markers
studied thus far having limited prognostic utility, or possibly
because of variable methodologies and populations used.8
Added to these issues are the small sizes of many of the
studies, which have been combined in meta-analyses that are
difficult to interpret because of methodological variability.
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To address these issues, we took a large patient popu-
lation and used tissue microarray technology to enable stain-
ing of numerous tissue samples at once, thereby minimizing
variability associated with multiple staining techniques, to
examine 11 biomarkers for their association with prognosis.
METHODS
Case Selection
Cases of primary NSCLC from patients with early stage
(stage I and II) disease, diagnosed between 1978 and 2002,
were identified from the archives of St. Paul’s hospital (A
large tertiary center in Vancouver, British Columbia). Other
than resectable lung cancer, no other specific selection crite-
ria were used. Tissue blocks were used to construct a dupli-
cate core tissue microarray. Carcinoids, atypical carcinoids,
large cell neuroendocrine carcinomas, and metastatic tumors
were all excluded.
Tissue Microarray Construction
Tissue microarrays were constructed as previously de-
scribed.25 Briefly, areas containing tumor were marked on the
paraffin tissue blocks. Sector maps were designed using
Microsoft Excel (Redmond, WA) spreadsheets to identify the
location of each specimen on the array blocks. Duplicate
0.6-mm tissue cores were used to construct the tissue mi-
croarrays with an arraying machine (Beecher Instruments Sun
Prairie, WI). Array blocks were sectioned to produce serial
4-m sections, and the first section was stained with hema-
toxylin and eosin to assess adequacy. The remaining sections
were stored at room temperature for 3 weeks before immu-
nostaining.
Biomarker Selection
Eleven biomarkers were chosen for assessment. The
markers were selected based on previous data suggesting
possible prognostic utility outlined in the introduction, and
antibody availability. The methods and results of the staining
for the neuroendocrine markers (Ch and SNP) have been
previously reported.26
Immunohistochemistry and Scoring
Staining for each marker was conducted using standard
antibodies (Table 1). The staining techniques varied accord-
ing to the manufactures recommendations. All samples were
evaluated and scored by two pathologists blinded to outcome
information. The scoring was performed independently and
the discrepant scores were resolved by double-scoping and
discussion of cases in question. A third pathologist was used
as an arbitrator for cases in which a consensus could not be
reached. The scoring system for the 11 biomarkers is sum-
marized in Table 2. The final results were reported as nega-
tive (score  0), positive (score  1, 2, or 3), or uninterpret-
able, with the exception of Her2 staining in which 0 and 1
are considered negative and 2 and 3 positive. Details of
Her2 scoring are reported elsewhere.27 Staining in nontumor
cells was not considered. The scores were entered into blank
sector maps of the corresponding array at the time of scoring,
and uninterpretable results were eliminated from further con-
sideration.
Data Analysis and Statistics
Data on the score sheets were converted into an Excel
spreadsheet format using the TMA-Deconvoluter program as
previously described.28 Score results for the duplicate cores
were consolidated into 1 score with higher positive staining
results always superseding weaker positive, negative, or un-
interpretable staining results.
Survival estimates were calculated for each outcome
(overall survival (OS) and disease-specific survival (DSS)),
and a log-rank statistic was used to test for differences
between groups. Log-rank statistics were used to look for any
relationships between biomarker expression and survival. A
significant difference was declared if the p value from a
two-tailed test was less than 0.05. Multivariate analysis using
age, and biomarker expression were tested using cox regres-
sion analysis. Statistical calculations were performed using
SPSS 13.0 software (SPSS, Chicago, IL).
RESULTS
The tissue microarray was constructed from 609 pa-
tients with early stage (stage I and II) NSCLC who had their
tumors resected between 1978 and 2002 (Table 3). A total of
588 of 609 cases were available for inclusion in the analysis.
Hematoxylin–eosin stained sections were reviewed and sub-
classified as follows: 243 adenocarcinoma (ACA), 272 squa-
mous cell carcinoma (SCC), 35 large cell carcinoma, 32
non-small cell carcinoma NOS, and 6 other (carcinoma, giant
cell carcinoma). Twenty-one cases were excluded because on
review, they were not considered to represent primary lung
tumor (12 cases), exhibited neuroendocrine differentiation
(three cases) or no pathologic diagnosis was available (six
cases). Table 4 provides a summary of the scoring results for
each biomarker. The results for Ch and SNP have been
previously reported.26 No prognostic significance was noted
for these two neuroendocrine markers.
Outcome data were available for 535 patients up to 26.5
years (median 3.52 years; range 34–9696 days) and these
were used for survival analysis. As of June 2005, 429 patients
(80%) had died; of these 286 (54%) died of lung cancer, 117
(22%) died of other known causes, and for 26 (5%) the cause
of death was not available (Table 3). The latter cases were
excluded from the DSS analysis.
TABLE 1. Biomarker Immunohistochemistry Assays
Biomarker Supplier Clone Dilution Antigen Retrival
p53 Dako D0-7 1:400 30 min heat with CC1
p63 Cell Marque 4A4 1:200 30 min heat with CC1
bcl-1 Neomarkers sp4 1:100 30 min heat with CC1
bcl-2 Dako 124 1:20 30 min heat with CC1
TTF Dako 8G7G3/1 1:100 30 min heat with CC1
CEA-mono Ventana TF-3H8-1 1:5 No antigen retrieval
EGFR Zymed 31G7 1:20 Protease 2–24 min
Her2 Neomarkers sp3 1:500 30 min heat with CC1
Her3 Neomarkers poly 1:10 30 min heat with CC1
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Univariate analysis was performed to look for an
association between biomarker expression and both OS
and DSS. Statistically significant associations were found
for bcl-2 with OS and for both bcl-2 and p63 with DSS
(Table 5). Of 470 samples successfully stained for bcl-2,
131 (28%) had positive expression for bcl-2 (59/194 ade-
nocarcinoma, 59/217 squamous cell carcinoma, 7/25
NSCLC not otherwise specified, 6/30 large cell carcinoma,
0/4 other). Of the 470 samples, 451 had outcome data
available. bcl-2 was the only biomarker found to have a
statistically significant correlation with OS (p  0.007)
(Figure 1) and DSS (p  0.021) (Figure 2).
A total of 476 samples were successfully stained for
p63, of which 171 (36%) positively expressed p63 (14/199
adenocarcinoma, 148/218 squamous cell carcinoma, 5/25
NSCLC not otherwise specified, 3/30 large cell carcinoma,
1/4 other). Of the 476 samples, 457 had outcome data
available. p63 expression was found to be associated with
DSS (p  0.025) (Figure 3). Four hundred seventy-eight
samples were successfully stained for EGFR. A total of
353/477 (74%) expressed EGFR (118/200 adenocarci-
noma, 191/217 squamous cell carcinoma, 19/25 NSCLC
not otherwise specified, 23/31 large cell carcinoma, 2/4
other). Of the 477 samples, 459 had outcome data avail-
able. EGFR expression was not associated with OS or DSS
in all NSCLC.
There were no significant associations between biomar-
ker expression and survival (OS and DSS) noted within
histologic subtypes (other than what would be expected by
chance alone), (Tables 6 and 7). For bcl-2, the relationship
between expression and OS was not significant within histo-
logic subtypes, other than in the small group of NSCLC not
otherwise specified adenocarcinoma (p  0.087), squamous
cell carcinoma (p  0.14), NSCLC not otherwise specified
(p 0.035), large cell carcinoma (p 0.162). These findings
may be related to the smaller sample size within the individ-
ual histologic subgroups.
A multivariate analysis model using age and biomarker
staining pattern was used to look for an association between
biomarker expression and OS. The only biomarker found to
have a significant association with survival was bcl-2. After
allowing for age, bcl-2 expression remained significantly
associated with increased survival, both OS (p  0.005) and
DSS (p  0.021) for all NSCLC. A further multivariate
analysis was conducted including age, gender, biomarker
expression, and histologic subtype. Stage was not included in
this analysis, because although all patients were early stage,
detailed staging information (stage I versus II) was not
available for most patients. The results again confirmed that
bcl-2 expression was associated with OS (p  0.004) and
DSS (p  0.018).
TABLE 2. Antibody Scoring System
Stain Name Staining Pattern
Score
0 1 2 3
p53 Nuclear 5 5–50 weak/moderate 5 strong OR 50 weak/moderate N/A
p63 Nuclear 5 5–50 weak/moderate 5 strong OR 50 weak/moderate N/A
Bcl-1 Cytoplasmic 5 5–50 weak/moderate 5 strong OR 50 weak/moderate N/A
Bcl-2 Cytoplasmic 5 5–50 weak/moderate 5 strong OR 50 weak/moderate N/A
TTF1 Nuclear 5 5–50 weak/moderate 5 strong OR 50 weak/moderate N/A
CEA Cytoplasmic 5 5–50 weak/moderate 5 strong OR 50 weak/moderate N/A
EGFR Nuclear/cytoplasmic 5 5–25 25–75 75
Her2 Membranous (see methods) N/A N/A N/A N/A
Her3 Nuclear/cytoplasmic 0 Any cells, weak Any cells, strong N/A
TABLE 3. Patient Characteristics (Outcomes as of June
2005)
Number (#) of male patients; Number of
female patients
400; 209
Age of diagnosis (mean; range) 63; 35–82
Ever smokers (#; percent) 438; 95%
n  459
No. of years of smoking (mean; range) 40; 0–69
Total # of patients with outcome data 535
Median survival (yr) 3.5 yr
Range of survival (d) 34–9673 d
Follow up (mean, range of yr) 5.8; 4–26.5
No. of living 106 (20%)
No. of deceased 429 (80%)
No. of died from lung cancer 286 (54%)
No. of died of other known causes 117 (22%)
No. of with cause of death unavailable 26 (5%)
TABLE 4. Biomarker Expression Scoring Results (See Table
2 for a Description of the Scoring System)
Biomarker Score: 0 (%) Score: 1 (%) Score: 2 (%) Score: 3 (%)
p53 (n  486) 46.4 21.1 32.4 N/A
p63 (n  476) 64.2 14.3 21.6 N/A
Bcl-1 (n  471) 25.6 33.1 41.3 N/A
Bcl-2 (n  470) 72.1 13.0 14.9 N/A
TTF (n  482) 67.3 11.4 21.3 N/A
CEA (n  473) 55.7 23.0 21.3 N/A
EGFR (n  477) 25.9 14.9 33.5 25.7
Her 2 (n  473) 86.3 10.5 2.3 0.9
Her 3 (n  475) 47.5 49.4 3.1 N/A
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DISCUSSION
A NSCLC tissue microarray was used to investigate the
associations between IHC markers and survival. Univariate
analyses demonstrated significant associations for bcl-2 with
OS, and both bcl-2 and p63 with DSS. After allowing for the
effect of age, only the association with bcl-2 expression
remained.
There has been extensive research on IHC biomarkers
in NSCLC with limited success in identifying markers that
have clinical utility. To date, none of the markers tested have
significant prognostic utility, which may reflect heterogeneity
in the methods used in these studies. Specifically, this relates
to variability in antibody use, scoring methods, and the
different disease stages of patients included. This heteroge-
neity is especially important when interpreting the numerous
meta-analyses that have been performed in this area. Through
the use of tissue microarray technology, we were able to
overcome many of these issues and study a large population
to identify several biomarkers that seem to have prognostic
utility, the most compelling being bcl-2.
bcl-2 is a proto-oncogene involved in cellular apopto-
sis. A meta-analysis performed in 2003 suggested that over-
expression of bcl-2 in NSCLC was associated with improved
survival.22 Using univariate analysis, we confirmed this, find-
ing bcl-2 expression to be associated with both OS (p 
0.007) and DSS (p  0.021). Multivariate analysis using age
and marker expression also revealed an association between
bcl-2 expression and both OS (p  0.012) and DSS (p 
0.029). These results suggest that bcl-2 expression is prog-
nostic for improved survival. In contrast, none of the other
biomarkers we examined demonstrated a strong association
with survival. Overexpression of p63, an analogue of p53, has
TABLE 5. Univariate Analysis of the Prognostic Significance
of Biomarkers on Overall Survival (OS) and Disease-Specific
Survival (DSS)
Biomarker
Association with OS
(All Non-small Cell
Lung Cancer) (P)
Association with DSS
(All Non-small Cell
Lung Cancer) (P)
p53 (n  467) 0.65 0.137
p63 (n  457) 0.29 0.025 (longer DSS)
Bcl-1 (n  452) 0.054 0.434
Bcl-2 (n  451) 0.007 (longer OS) 0.021 (longer DSS)
TTF (n  463) 0.188 0.799
CEA (n  454) 0.2 0.443
EGFR (n  459) 0.233 0.809
Her 2 (n  455) 0.611 0.635
Her 3 (n  457) 0.83 0.214
OS, overall survival; DSS, disease-specific survival.
FIGURE 1. Kaplan Meier curve of univariate analysis of
bcl-2 expression and overall survival (Total n  451; 5%
was interpreted as positive staining n  124; 5% was
interpreted as negative staining n  327).
FIGURE 2. Kaplan Meier curve of univariate analysis of
bcl-2 expression and disease-specific survival (Total n  451;
5% was interpreted as positive staining n  124; 5%
was interpreted as negative staining n  327).
FIGURE 3. Kaplan Meier curve of univariate analysis of p63
expression and disease-specific survival (Total n  457; 5%
was interpreted as positive staining n  165; 5% was
interpreted as negative staining n  292).
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previously been demonstrated to be associated with improved
survival.21 We also found p63 expression to be associated
with DSS in all NSCLC (p  0.025) using univariate anal-
ysis, but this association was no longer present after allowing
for the effect of age. We did not find any association of EGFR
expression and survival, in keeping with the findings of a
previous meta-analysis.12
It is unclear why expression of bcl-2 is associated with
improved prognosis. On the basis of the current understand-
ing of bcl-2 function, one would expect that bcl-2 expression
would enable cells to escape apoptosis and therefore would
be associated with a worse prognosis. One possible explana-
tion for why bcl-2 expression may be associated with a good
prognosis comes from the breast cancer literature. In breast
cancer, bcl-2 expression has also been associated with im-
proved prognosis. Martinez-Arribas et al.29 recently pub-
lished a study demonstrating that bcl-2 expression is associ-
ated with biologic features of tumors, which define a better
prognosis (in breast cancer these include hormone receptor
expression, absence of c-erb-B2, and mutant p53 expression).
Therefore, although bcl-2 may function to promote tumor
growth, its expression may be associated with other features
of tumors that define a more favorable prognosis.
There is interest in the targeted therapies against bcl-2,
and there is ongoing research regarding this therapeutic
modality in various tumor sites.30 In the future, bcl-2 may be
found to be a useful predictive marker to predict response to
these therapies. There is also a chance that bcl-2 expression
may have a predictive role regarding response to nontargeted
therapies. There is preliminary evidence31 that p53 expression
predicts response to vinorelbine and cisplatin. Further studies
are required to demonstrate whether bcl-2 expression has any
predictive role.
The major strength of this study is the use of a large
patient population to investigate biomarkers that may have
prognostic utility. Because of the large size, we are able to
avoid the heterogeneity that has made it difficult to interpret
meta-analyses of smaller studies. Our study provides com-
pelling evidence that bcl-2 is an important prognostic marker
in NSCLC, as it is associated with improved OS and DSS.
p63 may also have a prognostic role although our results are
less definitive. This study was limited in that no postsurgical
treatment information was available for the patients included
in the database, which may have contributed to differences in
survival. In addition, detailed staging information (stage I
versus II) was not available for most patients. A prospective
study is required to determine the clinical relevance of these
biomarkers, and our results suggest that bcl-2 is worthy of
such a trial. The hope for the future is that biomarkers such as
bcl-2 can be used to individualize prognosis and potentially
guide therapeutic decisions.
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